New hope for kids with tough kidney disease: obinutuzumab may replace steroids
NCT ID NCT07612592
First seen May 30, 2026 · Last updated Jun 15, 2026 · Updated 3 times
Summary
This study tests a new drug called obinutuzumab in 100 children aged 1-18 with refractory nephrotic syndrome, a kidney condition causing swelling and protein loss. The drug targets immune cells to reduce disease flares and dependence on steroids and other medications. Researchers aim to see if it works better than an older similar drug (rituximab) and helps more children achieve remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY NEPHROTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chongqing medical university
Chongqing, Chongqing Municipality, 400014, China
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.